Pharma-2020: Technological aspects of production of some strategical biopharmaceuticals

Russian Journal of Biopharmaceuticals

Volumn 4, Issue 3, 2012, Pages 21-45

  Kurbanova, E K ^a,b   Chulkova, T Y ^a   Byrikhina, D V ^a   Dano, A O ^a   Nikolaeva, V A ^a   Gusarov, D A ^a,b  

^a MIREA RUSSIAN TECHNOLOGICAL UNIVERSITY   (Russian Federation)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Biosimilar; Chromatography; Production process; Recombinant protein

Indexed keywords

ALTEPLASE; BETA INTERFERON; BLOOD CLOTTING FACTOR 9; CETUXIMAB; ERYTHROPOIETIN; IMIGLUCERASE; INSULIN DERIVATIVE; RECOMBINANT FOLLITROPIN; RITUXIMAB; TRASTUZUMAB;

BIOTECHNOLOGICAL PRODUCTION; DRUG INDUSTRY; REVIEW;

EID: 84866417479     PISSN: 20738099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Russian Source.
2. URL: http://www.who.int/mediacentre/factsheets/fs312/ru/index.html.
3. Alastair J. J., Wood M. D. N. Engl. Med. 1997. V. 337. P. 176-183.
4. Setter S. M., Corbett C. F., Campbell P. K., White J. R. Ann. Pharmacother. 2000. V. 34. P. 1423-1431.
5. Markussen J., et al. Diabetologia. 1996. V. 39. P. 281-288.
6. Whittingham J. L., et al. Biochemistry. 1997. V. 36. P. 2826-2831.
7. Chance R. E., Di Marchi R. D. Frank B. H. Shields J. E. Insulin Analogs Modified at Position 29 of the B Chain, United States Patent No. 5514646, 1996.
8. Graumann K., Premstaller A. J. Biotechnol. 2006. V. 1(2). P. 164-186.
9. Winter J., Neubauer P., Glockshuber R., Rudolph R. J. Boitechnol. 2000. V. 84. P. 175-185.
10. Russian Source.
11. Zimmerman, et al. Insulin production methods and pro-insulin constructs, United States Patent No. 7790677 B2, 2010.
12. Cregg J. M., et al. Mol. Cell Biol. 1985. V. 5. No. 12. P. 3376-3385.
13. Russian Source.
14. Annibali, et al. Process for obtaining aspart insulin using Pichia pastoris yeast strain, United States Patent No. 0117600 A1, 2011.
15. Hazra Partha, et al. A process for preparation of insulin compounds, World Intellectual Property Organization Patent Apllication, WO 2009/104199 A1, 2009.
16. Bogsnes A., et al. Process for preparing insulin compounds, World Intellectual Property Organization Patent Apllication, WO 03/044210 A2, 2003.
17. Derynck R., Content J., DeClercq E., Volckaert G., Tavernier J., Devos R., Fiers W. Nature. 1980. V. 285. P. 542-547.
18. Lin L. Dev. Biol. Stand. 1998. V. 96, P. 97-104.
19. McCormick F. P., et al. Human interferon-b produced in chinese hamster ovary (CHO) cells, United States Patent No. 5795779, 1998.
20. Mark D. F., et al. Structural genes, plasmids and transformed cells for producing cysteinr depleted muteins of interferon-b, United States Patent No. 4737462, 1988.
21. Russian Source.
22. Ze'ev Shaked, Wolfe S. N. Controlled oxidation of microbially produced cysteine-containing proteins, United States Patent No. 4530787, 1985.
23. Russell-Harde D., Knauf M., Croze E. J. Interferon Cytokine Res. 1995. V. 15. P. 31-37.
24. Russian Source.
25. Russian Source.
26. Russian Source.
27. Furbish F. S., Blair H. E., Shiloacht J., et al. Proc. Natl. Acad. Sci. USA. 1987. V. 74. No 8. P. 3560-3563.
28. Friedman B., Hayes M. Enhanced in vivo uptake of glucocerebrosidase, United States Patent No. 5549892, 1996.
29. Ma J. K. C., Drake P. M. W., Christou P. Nature Rev. Genet. 2003. V. 4. P. 794-805.
30. Pennica D., Holmes W. E., et al. Nature. 1983. V. 301. P. 214-221.
31. Goeddel D. V., Kohr W. J., Pennica D., Vehar G. A. Human tissue plasminogen activator, United States Patent No. 5702938, 1997.
32. Tharmalingam T., et al. Mol. Biotechnol. 2008. V. 39. P. 167-177.
33. Ng Y. C., Berry J. M., Butler M. Biotech. Bioeng. 1996. V. 50. P. 627-635.
34. Tharmalingam T., et al. Mol. Biotechnol. 2011. V. 49. P. 263-276.
35. Patell V. M. Method for production of a bioengineered form of tissue plasminogen activator, United States Patent No. 0246188, 2009.
36. Prior C. P., Hope J., Tolbert W. R. A process for obtaining higher yields of unaggregated tissue plasminogen activator from cell culture, Eur. Pat. Applic. No. 0309111, 1989.
37. Qiu J., Swartz J. R., Georgiou G. Appl. Environ. Microbiol. 1998. V. 64. P. 4891-4896.
38. Rijken D. C., Collen D. J. Biol. Chem. 1981. V. 256. P. 7035-7041.
39. Furlong A. M., Thomsen D. R., et al. Biotechnol. Appl. Biochem. 1988. V. 10. P. 454-464.
40. Ogrydziak D. M. Crit. Rev. Biotechnol. 1993. V. 13. P. 1-55.
41. Yong Cheng. Method for producing human tissue plasmin activator, Chin. Pat. Applic. No. 101492662, 2009.
42. Hunh Bum Soo, Kim Yong Hwan, et al. Vector comprising tissue-type plasminogen activator gene, hairy root transformed thereby and method for preparing tissue-type plasminogen activator using the same, Patent KR No. 100887367, 2007.
43. Heussen C., Joubert F., Dowdle E. B. J. Biol. Chem. 1984. V. 259. P. 11635-11638.
44. Randy et al. FEBS Lett. 1982. V. 146. P. 289-292.
45. Mori T., Yoshizaki H., Hasegawa A. Purified plasminogen activator, process for its production and thrombolytin composition containing it, United States Patent No. 4505893, 1985.
46. Morii M., Kawashima N., Mori K., Ohoka M. Method for purifying a crude tissue plasminogen activator preparation, United States Patent No. 5158882, 1992.
47. Sudip K. M., Gita A., Bhavesh S. Process for purufucation of human tissue type plasminogen activator, Eur. Pat. Applic. No. 2193197, 2009.
48. Russian Source.
49. Russian Source.
50. Russian Source.
51. Artymiuk P., Ross R., Sayers J. Erythropoietin, United States Patent No. 0275564 A1, 2011.
52. Fu-Kuen Lin. Production of erythropoietin, United States Patent No. 5547933, 1995.
53. URL: http://www.medicusamicus.com/index.php?action=2x1854x1
54. Russian Source.
55. Owren P. A., Stormorken H. The Mechanism of Blood Coagulation. Springer-Verlag, 1973. 53 p.
56. Russian Source.
57. Teitel J. M. Haemophilia. 1998. V. 4. P. 393-401.
58. Russian Source.
59. Russian Source.
60. Russian Source.
61. Foster B. W., et al. Factor IX purification methods, United States Patent No. 6627737 B1, 2003.
62. Hoffman J. A., Lu J. FSH and FSH variant formulations, products and methods, United States Patent No. 7563763, 2009.
63. Murphy G., Cockett M. I., Ward R. V., Docherty A. J. Biochem. J. 1991. V. 227. P. 277-279.
64. Muda M., Jiang X., McKenna S. D. FSH mutants, United States Patent No. 7740862, 2010.
65. Lustbader J. Long-acting follicle stimulating hormone analogues and uses thereof, United States Patent No. 7807620, 2010.
66. Samaritani F., Donati P. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic, United States Patent No. 7741268, 2010.
67. Rossi M. Method of purifying FSH, United States Patent No. 7754860, 2010.
68. Samaritani F., Donati P. Freeze-dried FSHLH formulations, United States Patent No. 7740884, 2010.
69. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Scientific_Discussion/human/000558/WC500029113.pdf.
70. Ciardiello F., Bianco R., Damiano V., et al. Clin. Cancer Res. 1999. V. 5. No 4. P. 909-916.
71. Goldstein N. S., Armin M. Cancer. 2001. V. 92. No 5. P. 1331-1346.
72. Orton R. J., Sturm O. E., Vyshemirsky V., et al. Biochem. J. 2005. V. 392. P. 249-261.
73. Patell V. M., Guzder S. N., Maity S., Shekar S. A highly efficient process of purification of recombinant cetuximab, World Intellectual Property Organization Patent Apllication, WO 2011/015921 A1, 2011.
74. Vogel C. L., Cobleigh M. A., Tripathy D., et al. J. Clin. Oncol. 2002. V. 3. {Eth}. 719-726.
75. Basey C. D., Blank G. S. Protein purification, United States Patent No. 6339142, 2002.
76. Bryant J. L. Herceptin aduvant therapy, United States Patent No. 0003217, 2012.
77. McLean M. D., Chen R., Yu D., Mah K. Z., Teat J. Transgenic research. 2012-electronic supplementary material (http://www.springerlink. com/content/mu7k002428255jr4/).
78. Patell V. M., Guzder S. N., Maity S., Shekar S. A highly efficient process of purificatiom and production of recombinant trastuzumab, World Intellectual Property Organization Patent Apllication, WO 2011/015920, 2011.
79. Adler M., Grauschopf U., Mahler H. C., Stauch O. B. Subcutaneous anti-HER2 antibody formulations and uses thereof, United States Patent No. 0044977 A1, 2011.
80. Anderson D. R., Hanna N., Newman R. A., Reff M. E., Rastetter W. H. Expression and use of anti-CD20 antibodies, United States Patent No. 7381560, 2008.
81. Reff M., Carner K., Chambers K., et al. Blood. 1994. V. 83. No 2. P. 435-445.
82. Anderson D. R., Hanna N., Leonard J. E., Newman R. A., et al. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma, United States Patent No. 5736137, 1998.
83. Berthold W., et al. The Rituxan Story: The Journey of a chimeric antibody at a conference entitled Recovery of biological products 10: Learning for the future. Cancun, Mexico, 2001.
84. Lebreton B. A., O'Connor D. A., Safta A., Sharma M. Antibody purification bu cation exchange chromatography, United States Patent No. 0148435, 2009.
85. Adler M., Mahler H., Stauch O. B. Highly concentrated pharmaceutical formulation comprising anti-CD20 antibody, World Intellectual Property Organization Patent Apllication, WO 2011/029892, 2011.
86. Gottschalk U. Process scale purification of antibodies. Wiley, 2011.
87. Zhou J. Methods for Removing Viral Contaminants During Protein Purification, United States Patent No. 0132688, 2008.